Search

Search Constraints

You searched for: Author/Creator Godwood, Alex

Search Results

1. A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease. Issue 1 (23rd February 2022)

2. A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Issue 6 (17th February 2017)

3. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Issue 1 (27th December 2017)

4. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis. (23rd October 2017)

6. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Issue 9 (12th December 2012)

7. Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody: Long‐Term Safety and Efficacy in Patients With Rheumatoid Arthritis. Issue 5 (31st March 2018)

8. P3‐100: CH 1, 2, AND 3 BASAL FOREBRAIN NUCLEI VOLUMES PREDICT FUNCTIONAL SENSITIVITY TO MUSCARINIC M1 RECEPTOR ANTAGONIST BIPERIDEN ON DELAYED WORD RECALL. (1st July 2019)